


MOSS-FH

FOR C3G

Moss-FH is a recombinant protein in development as a treatment for C3 Glomerulopathy (C3G).

The structure is identical with human factor H, a regulator of complement activation.



GREENOVATION
Biopharmaceuticals

Greenovation Biotech GmbH
Hans-Bunte-Str. 19, 79108 Freiburg, Germany
© 2017 Greenovation Biotech GmbH

JASN


MOSS-PRODUCED, GLYCOSYLATION-OPTIMIZED HUMAN FACTOR H FOR THERAPEUTIC APPLICATION IN COMPLEMENT DISORDERS.

Journal of the American Society of Nephrology, 2017, 28 (5): 1462–1474

Moss-FH reduces C3 deposition in diseased mice

Moss-FH is designed to replace the missing or reduced activity of human complement factor H in patients with life-threatening diseases such as C3G, aHUS and PNH. In C3G, the deposition of complement component 3 (C3) in the filtration units of the kidney (glomeruli) leads to substantial damage and ultimately to end stage renal disease. Treatment with moss-FH has the potential for considerable improvements of patients' quality of life.

+ Preclinical trials show treatment with moss-FH reduces C3 deposits in mice kidney



Measurement of C3 deposition in kidney glomeruli in untreated and moss-FH-treated diseased mice, and healthy controls